Oct 6 2009, 11:10 AM EST
GEN News Highlights
Quidel will be developing in vitro molecular diagnostic tests utilizing BioHelix’ isothermal-amplification technology. BioHelix’ expertise in the R&D of nucleic acid technologies for diagnostic applications will be combined with Quidel’s strength in the development, manufacture, and commercialization of such tests.
Under the development and commercialization agreement, Quidel will fund and jointly develop with BioHelix assays for rapid detection of infectious pathogens in a noninstrumented, handheld format. BioHelix will have primary responsibility for assay development. Quidel will have exclusive, worldwide commercialization rights for the new products. It will also undertake all manufacturing and marketing.
BioHelix’ IsoAmp® Molecular Analyzer is an instrument-free molecular diagnostic platform consisting of its Helicase-Dependent Amplification technology and a disposable detection device entitled the BESt™ Cassette.
♦♦♦
Related News
DxS and Epigenomics Cross-License Technologies for DNA Methylation In Vitro Diagnostics (July 20, 2009)
Nanogen Licenses Technology to Quest for In Vitro Diagnostic Testing (Mar. 4, 2009)
Sienna to Leverage Geron IP in the In Vitro Cancer Diagnostics Segment (Jan. 24, 2008)
Quidel In-Licenses Flu Antiviral Resistance and Detection Tool (July 17, 2007)
Quidel Licenses MChip from University of Colorado (Dec. 19, 2006)
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More GEN News Highlights
Listen
Save
Comment
View All